India, July 6 -- Glenmark Pharmaceuticals has outlined its innovation roadmaps, setting a target of filing one Investigational New Drug (IND) application every year beginning FY27 as it seeks to strengthen its research-led pharmaceutical business across oncology, dermatology and respiratory therapies.

At its Investor Day, a meeting held annually with industry analysts, the company positioned Ichnos Glenmark Innovation (IGI) at the centre of this strategy, with a continued focus on developing next-generation biologics, particularly multispecific antibodies for oncology. Its proprietary BEAT (Bispecific Engagement by Antibodies based on the T-cell receptor) platform will remain a key area of investment to support the discovery of such nove...